Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00962832 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Efficacy and Safety of Rontalizumab in Patients With Moderately to Severely Active Systemic Lupus Erythematosus
A Phase 2 study, sponsored by Genentech.
- Completed
- Registry status
- Phase 2
- Development phase
- 238
- Enrollment target
NCT00962832 is a Phase 2 study that has completed, run by Genentech. The registered enrollment target is 238 participants.
The verdict
NCT00962832, a Phase 2 study, has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 238 participants
- Enrollment target
Study Summary
This is a Phase II, randomized, double-blind, placebo-controlled multicenter study to evaluate the efficacy and safety of rontalizumab compared with placebo in patients with moderately to severely active systemic lupus erythematosus (SLE).
Interventions
- DRUG Placebo
- DRUG Rontalizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 238 participants |
| Start Date | 2009-09 |
| Est. Completion | 2013-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00962832
The ClinicalTrials.gov registry entry for NCT00962832 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 238 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00962832 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00962832 about?
NCT00962832 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of Rontalizumab in Patients With Moderately to Severely Active Systemic Lupus Erythematosus". This is a Phase II, randomized, double-blind, placebo-controlled multicenter study to evaluate the efficacy and safety of rontalizumab compared with placebo in patients with moderately to severely active systemic lupus erythematosus (SLE).
What is the current status of trial NCT00962832?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 238 participants. The study started on 2009-09. Estimated completion is 2013-08.
What interventions are being tested in trial NCT00962832?
The interventions under investigation include: Placebo (DRUG), Rontalizumab (DRUG).
Who is sponsoring clinical trial NCT00962832?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.